Currently Viewing:
In Focus Blog

Liraglutide Lowers A1C in Youth With Type 2 Diabetes, Phase 3 Study Finds

Mary Caffrey
The results may lead to the first new option in years for youth with type 2 diabetes, besides metformin and insulin.
Youth with type 2 diabetes (T2D) who were treated with liraglutide had significantly lower average blood sugar after a year than those treated with placebo, according to results of a phase 3 study reported today in the New England Journal of Medicine. Results were presented at the Pediatric Academic Societies meeting in Baltimore, Maryland.

The findings could lead to the first new treatment option in 20 years for children and teens who have T2D; right now, those younger than age 18 who cannot achieve glycemic control with metformin have only insulin as an FDA-approved option. Experts in the diabetes community say more choices are needed for these patients, whose diabetes progresses rapidly and whose ranks are growing, driven by childhood obesity.

The study, called the Ellipse trial (Evaluation of Liraglutide in Pediatrics with Diabetes), took more than 5 years to complete given the challenges of enrolling 135 patients aged 10 to 17, as well as regulatory requirements to include a diverse group and adequate numbers older and younger than 14 years of age. Novo Nordisk, which markets the glucagon-like peptide-1 (GLP-1) receptor agonist it markets to adults as Victoza, funded the study.

Novo Nordisk officials said in a statement that the Ellipse results have been submitted to regulators at FDA and the European Medicines Agency for evaluation as a potential treatment option for children 10 years and above with type 2 diabetes.

“We are delighted with the ELLIPSE trial results and look forward to discussions with the FDA and EMA about these data for Victoza®," said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. "These data add to the extensive evidence for the use of Victoza and further cement Novo Nordisk's commitment to addressing a considerable and growing unmet medical need across the full spectrum of the type 2 diabetes patient population.”

As seen with adults taking the drug, patients taking liraglutide had more gastrointestinal problems. Fasting plasma glucose decreased in the liraglutide group but rose in the placebo group. Surprisingly, while adults taking the drug often lose weight, there was no significant difference in a score of body mass index (BMI) at 26 weeks for youth; both pediatric groups lost weight by week 26 but only the liraglutide group maintained it at 52 weeks.

Researchers led by William V. Tamborlane, MD, chief of pediatric endocrinology at Yale School of Medicine, randomized the patients into 2 groups; some were already taking insulin or metformin. A run-in period put patients on a maximum tolerated dose of metformin, between 1000 mg and 2000 mg per day, and patients taking insulin had their dose stabilized. (Patients taking more than 2000 mg metformin stayed on that dose.) Diet and exercise counseling were provided.

Liraglutide doses began at 0.6 mg and were increased to 1.2 mg or 1.8 mg, which is the approved FDA dose for adults, based on side effects and fasting plasma glucose tests. At the start of the study, patients on insulin cut their dose by 20%, but if necessary they could return to their old dose once the liraglutide dose was escalated.

Results showed the following:
  • Doses for liraglutide and placebo were blinded for 26 weeks. At that point, glycated hemoglobin (A1C) in the group taking the study drug had decreased 0.64 percentage points, while those taking placebo saw their A1C increase by 0.42 percentage points, for a difference of -1.06 percentage points (P < .001).
  • After 26 weeks, the liraglutide group continued taking it in an open-label study, while the others stopped taking the placebo but continued on metformin. At 52 weeks, the liraglutide group had reduced A1C 0.50 percentage points from baseline while the placebo group had increased A1C 0.80 percentage points from baseline, for a difference of -1.30 percentage points.
  • Differences in fasting plasma glucose at 26 weeks were: –1.08 mmol/L for liraglutide, compared with +0.80 mmol/L for placebo. At 52, the liraglutide group was –1.03 mmol/L; the group that had taken placebo was +0.78 mmol/L from baseline.
  • Overall, 63.7% of those in the liraglutide group attained A1C levels below 7.0%, which is the recommended level of glycemic control from the American Diabetes Association. Only 36.5% in the placebo group achieved A1C below A1C.
  • Adverse events (AEs) were higher in the liraglutide group, especially in the first 8 weeks, with the common events being nausea (19 patients), vomiting (17 patients), and diarrhea (15 patients). Nine patients reported serious events, and 6 reported medical events of special interest. One patient stopped taking the drug because of AEs.
  • The study had provisions for rescue therapy; 71.2% of the liraglutide group and 50.7% of the placebo group reached week 52 without it.
  • The investigators speculate that the titrating schedule, the fact that some patients never achieved the maximum dose, or the fact that some were still growing may account for BMI results that did not match those seen in adults. At the end of week 3, only 55.6% of the patients in the liraglutide group were taking the maximum dose.
T2D in Youth Progresses Quickly
The Ellipse investigators studied young patients who were typical of those who develop T2D at young ages: with an average age of 14.6 years and BMI of 33.9 kg/m2, they had lived with T2D for slightly less than 2 years but already had an average A1C of 7.87%. (Patients in the study had A1C of 7% to 11%, or 6.5% to 11% if they were already taking metformin).

According to a 2011 Diabetes Care review of the progression of T2D in youth, a diagnosis typically comes around age 13.5 years, or mid-puberty, and is accompanied by a significant loss of β-cell function. “In fact,” wrote authors Amanda Flint, MD, and Silva Arslanian, MD, “adolescents with type 2 diabetes have ~50% lower insulin sensitivity and ~75% lower first-phase insulin secretion when compared with nondiabetic adolescents matched for BMI and abdominal adiposity.” Puberty is the trigger, and the rapid loss of glycemic control—coming in months, not years—among young teens with new onset T2D was further explained in the TODAY study, which found it to be 3- or 4-fold the rate of adults.

As Tamborlane and fellow investigators note, not only youth with T2D have acute needs, but there more of them, especially among minority groups as rising childhood obesity rates put more youth at risk. CDC data that obesity prevalence is 13.9% among 2- to 5-year-olds, and prevalence rises with age until it reaches 20.6% among 12- to 19-year-olds. But the distribution of obesity is uneven—rates are much higher among African Americans and Hispanics, and particularly high among African American females and Hispanic males.

A 2017 National Institutes of Health study (SEARCH) reported that from 2003 to 2012 among youth age 10-19, the rate of newly diagnosed T2D cases rose 6.3% among African Americans, 8.5% among Asian Americans/Pacific Islanders, and 3.1% among Hispanics. An increase of 8.9% among Native Americans was from a sample size too small to be generalized across the population.



Related Articles

Liraglutide Approved Under New Name to Treat Obesity
Dr Fatima Cody Stanford Emphasizes Role of Family in Treating Childhood Obesity
Mississippi Taking Steps to Reduce Childhood Obesity
JDRF's Kowalski Asks Payers to Get Behind "Beyond A1C"
 
Copyright AJMC 2006-2020 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up